Endo Health Solutions, Inc. (NASDAQ:ENDP)

not2eager (69.43) Submitted: 9/20/2007 2:08:20 PM : Start Price: $31.07 ENDP Score: +17.07

Look at the weekly chart. In an upward channel. Makes money in an undervalued sector. Cheap P/E, an in the low end of the channel.

Thegreatdoodle (< 20) Submitted: 9/6/2007 8:15:47 PM : Start Price: $31.89 ENDP Score: +10.33

I like the PE and the low public profile of this company

antman02 (68.38) Submitted: 7/23/2007 3:57:25 PM : Start Price: $34.22 ENDP Score: +7.79

Endo is poised to make a move up from here. Look for the brokerage houses to ride this baby to ~ $38 prior to the next earnings call. Product sales growth will be on the high side - no "pain" here !

ranaxy (58.33) Submitted: 6/1/2007 1:16:28 PM : Start Price: $27.96 ENDP Score: +20.06

I am not sure why I added this into my portfolio, but its doing great! I found it when researching RDY, and S&P reports on RDY included ENDP as a competitor. Hopefully, someday I shall update this as to why I think this stock is moving up.

shatch24 (46.64) Submitted: 4/30/2007 10:32:42 PM : Start Price: $30.76 ENDP Score: +15.04

Solid group of pain medications on the market, with several more in the pipeline. Even at a 10% earnings growth (10/5/3) over the next five years, the DCF puts this stock in the mid 40s. Up that growth to 15% and its in the 50s.

prumoose (< 20) Submitted: 1/21/2007 4:36:43 PM : Start Price: $29.78 ENDP Score: +14.72

hysteria/overreaction over the

OzSmall (93.56) Submitted: 1/20/2007 8:37:43 AM : Start Price: $29.78 ENDP Score: +14.72

pressure on lidoderm patents will have to keep them looking for acquisitions to protect market share and $$

Wicon (< 20) Submitted: 1/19/2007 4:49:28 PM : Start Price: $29.78 ENDP Score: +14.72

This company is specialized in a niche area - pain management, and is clearly the market leader.

Expiration of Lidoderm patents is still years away, and the company has already launched new products and has two more new products in phase III. It has sufficient time to balance out the potential pitfall of Lidoderm patents.

Recent weakness provides a good entry point.

mnsw (< 20) Submitted: 1/19/2007 11:43:33 AM : Start Price: $29.89 ENDP Score: +14.13

Lidoderm is still a cash cow, although generic risks will be coming soon. The pipeline has numerous drugs in phase 2 and 3 that

dch1dch2 (< 20) Submitted: 11/19/2006 2:22:37 PM : Start Price: $29.12 ENDP Score: +15.18

Maker of generic pain meds for an ever increasinf population of baby boomers looking for a price break.

prewitt (< 20) Submitted: 10/10/2006 4:23:34 PM : Start Price: $33.38 ENDP Score: -3.42

A leader in its field

topreader (79.22) Submitted: 9/22/2006 6:59:09 AM : Start Price: $31.97 ENDP Score: -1.51

Company in a leader in pain management.